Fluorinated Gabapentin Derivatives for Neuropathic Pain PET Imaging

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack effective and objective measures for assessing the efficacy of new pain medications, particularly for neuropathic pain, and there is a need for a PET tracer that can specifically image neuropathic pain, as no such tracers exist, and identifying a biological target like the α2δ-1 subunit of voltage-gated calcium channels is crucial for developing such imaging agents.

Innovation Solution

Development of fluorinated gabapentin derivatives, specifically radiolabeled with 18F, which bind selectively to the α2δ-1 subunit, allowing for PET imaging of neuropathic pain and potentially other conditions like epilepsy and anxiety, through their synthesis and use in pharmaceutical compositions for both diagnostic imaging and therapeutic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional pain assessment methods are used, then subjective reporting is obtained, but objectivity and precision of measurement are insufficient

Engineering Contradiction:

Improveprecision of pain assessmentVSAvoidsubjectivity in pain evaluation

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent replaces subjective mechanical assessment methods with PET imaging technology that uses radioactive tracers to objectively visualize and quantify neuropathic pain through biochemical markers, transforming pain assessment from subjective reporting to objective molecular imaging

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent employs PET imaging that produces visual images showing the distribution and concentration of radiolabeled tracers in the body, with image intensity corresponding to pain-related biochemical activity, enabling objective visualization of pain states

Inventive Principle:

Principle #32Color changes

2Measurement precision

If PET tracers are developed for neuropathic pain imaging, then specific biochemical information is obtained, but device complexity and manufacturing difficulty increase

Engineering Contradiction:

Improvespecificity of neuropathic pain imagingVSAvoidcomplexity of radiolabeled compound synthesis

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent divides the radiolabeled compound into a stable parent compound (gabapentin derivative) and a radioactive label (18F), allowing the parent compound to be synthesized once and stored, while only the radioactive label needs to be produced fresh, simplifying the overall process

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary synthesis of the parent gabapentin derivative compound before radiolabeling, so that the chemical structure is established and validated in advance, requiring only the addition of the radioactive fluorine-18 label during the imaging procedure

Inventive Principle:

Principle #10Preliminary action

3Measurement precision

If radiolabeled gabapentin derivatives are used for imaging, then diagnostic capability is improved, but loss of time in tracer production and administration occurs

Engineering Contradiction:

Improvediagnostic accuracy of neuropathic painVSAvoidtime for tracer synthesis and administration

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent utilizes the positron emission and annihilation radiation from fluorine-18 decay, which occurs with a half-life of approximately 110 minutes, providing sufficient time for tracer synthesis, quality control, and administration while maintaining high diagnostic precision

Inventive Principle:

Principle #18Mechanical vibration

Solution Approach 2:

The patent selects fluorine-18 as the radioactive label specifically because its 110-minute half-life provides an optimal balance between maintaining sufficient radioactivity for high-quality imaging and allowing adequate time for tracer preparation and administration procedures

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The 18F-labeled gabapentin derivatives effectively bind to α2δ-1 receptors, providing a means to image and diagnose neuropathic pain, with trans-[18F]4F-GBP showing higher binding affinity, enabling precise biochemical information and potential therapeutic benefits.

Implementation Method 1

the fluorine atom is 18F

Methodology Applied

Scientific EffectRadioactive decay: Radioactive Decay

Implementation Method 2

detecting the compound comprises using Positron Emission Tomography (PET) to obtain an image of the compound in the subject

Methodology Applied

Scientific EffectPET imaging: Tomography

Data Source

PatentUS20230150922A1Fluorinated Derivatives of Gabapentin and Methods of Use Thereof

Publication Date: 2023.05.18 THE GENERAL HOSPITAL CORP

AI summary

Described herein are fluorinated derivatives of gabapentin and methods of synthesis and methods of use thereof, e.g., in imaging and therapy.